You are here

Article Text

Article menu
Download PDFPDF
Original Articles: PDF Only
Retrospective review of 41 patients with endodermal sinus tumor of the ovary
  1. M. Fujita*,
  2. M. Inoue*,
  3. O. Tanizawa*,
  4. J. Minagawa†,
  5. T. Yamada† and
  6. T. Tani‡
  1. * Department of Obstetrics and Gynecology, Osaka University Medical School,
  2. † Department of Obstetrics and Gynecology, Minoh City Hospital, and
  3. ‡ Department of Obstetrics and Gynecology, Osaka Kaisei Hospital, Osaka, Japan
  1. Address for correspondence: Masaki Inoue, MD, Department of Obstetrics and Gynecology, Osaka University Medical School, 1-1-50, Fukushima Fukushima-ku, Osaka 553, Japan.

Abstract

Forty-one patients with endodermal sinus tumors of the ovary (EST) (23: pure EST, nine: EST with dysgerminoma; and nine: EST with immature teratoma) were treated with cytoreductive surgery, with or without subsequent adjuvant chemotherapy including VAC or PVB. Clinical staging of these patients showed 23 in stage I, six in stage II and 12 in stage III and IV. The outcome was good in the patients with stage I or II disease, with 5- and 10-year survival rates of around 80%. In contrast, all except two patients with stage III or IV disease died within 2 years. Aggressive surgery did not change the outcome of patients with stage I disease. In addition, postoperative chemotherapy was necessary, but the choice of vincristine, actinomycin-D and cyclophosphamide (VAC) or cis-platin, vinblastine and bleomycin (PVB) did not make any difference. Based on the results of the present study, VAC or PVB chemotherapy, after cytoreductive surgery, is essential for cure and conservative surgery followed by VAC or PVB regimen should be recommended for young patients.

  • chemotherapy
  • conservative operation
  • long-term outcome
  • ovarian endodermal sinus tumor.

https://doi.org/10.1046/j.1525-1438.1993.03050329.x

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.